7/8 February 2023
The Questions & Answers (Q&A) documents relating to centralised marketing authorisation procedures, last revised in June, have now been updated again and published on the European Medicines Agency (EMA) website. These Q&As are intended to provide guidance and guidelines for marketing authorisation holders and applicants of centralised procedures and provide answers to potential questions at different stages of the centralised marketing authorisation application process.
The list of questions with regard to topics prior to and during the application for a centralised procedure - "European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure" - has been extended respectively updated with the following points
In paragraph 3.3. Quality, question 3.3.1. "What information relating to the manufacturing, testing and batch release sites should be provided as part of my application?" and its answer have been revised and the item "testing" has been added.
In paragraph 5.2. Inspections, section 188.8.131.52. Pre-submisson notification has been amended by several passages and the item "testing" has also been added.
The new version of the Q&A document "European Medicines Agency post-authorisation procedural advice for users of the centralised procedure", addressing issues that may be relevant after marketing authorisation, contains some additions, revisions and innovations in the following passages:
There were updates in the following three questions:
The new versions of the "Q&A" documents for central procedures can be found at: